Share on StockTwits

ACADIA Pharmaceuticals (NASDAQ:ACAD) CEO Uli Hacksell unloaded 20,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $23.10, for a total value of $462,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 1.94% on Wednesday, hitting $23.67. The stock had a trading volume of 649,948 shares. ACADIA Pharmaceuticals has a 1-year low of $15.64 and a 1-year high of $32.00. The stock’s 50-day moving average is $20.48 and its 200-day moving average is $23.23. The company’s market cap is $2.343 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.06. Analysts expect that ACADIA Pharmaceuticals will post $-0.80 EPS for the current fiscal year.

A number of research firms have recently commented on ACAD. Analysts at Morgan Joseph initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Thursday, May 15th. They set an “overweight” rating on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Thursday, May 15th. They set an “overweight” rating and a $33.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. ACADIA Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $27.33.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.